<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://ltrc.sciwiki.in/index.php?action=history&amp;feed=atom&amp;title=%E0%A6%9F%E0%A6%BE%E0%A6%B0%E0%A6%BE%E0%A6%A8%E0%A6%BE%E0%A6%AC%E0%A7%8D%E0%A6%AF%E0%A6%BE%E0%A6%A8%E0%A7%8D%E0%A6%9F</id>
	<title>টারানাব্যান্ট - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://ltrc.sciwiki.in/index.php?action=history&amp;feed=atom&amp;title=%E0%A6%9F%E0%A6%BE%E0%A6%B0%E0%A6%BE%E0%A6%A8%E0%A6%BE%E0%A6%AC%E0%A7%8D%E0%A6%AF%E0%A6%BE%E0%A6%A8%E0%A7%8D%E0%A6%9F"/>
	<link rel="alternate" type="text/html" href="https://ltrc.sciwiki.in/index.php?title=%E0%A6%9F%E0%A6%BE%E0%A6%B0%E0%A6%BE%E0%A6%A8%E0%A6%BE%E0%A6%AC%E0%A7%8D%E0%A6%AF%E0%A6%BE%E0%A6%A8%E0%A7%8D%E0%A6%9F&amp;action=history"/>
	<updated>2026-10-19T08:39:58Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.9</generator>
	<entry>
		<id>https://ltrc.sciwiki.in/index.php?title=%E0%A6%9F%E0%A6%BE%E0%A6%B0%E0%A6%BE%E0%A6%A8%E0%A6%BE%E0%A6%AC%E0%A7%8D%E0%A6%AF%E0%A6%BE%E0%A6%A8%E0%A7%8D%E0%A6%9F&amp;diff=6729&amp;oldid=prev</id>
		<title>Digantasen: ইংরেজি উইকিপিডিয়ার “Taranabant” নিবন্ধের বাংলা অনুবাদ</title>
		<link rel="alternate" type="text/html" href="https://ltrc.sciwiki.in/index.php?title=%E0%A6%9F%E0%A6%BE%E0%A6%B0%E0%A6%BE%E0%A6%A8%E0%A6%BE%E0%A6%AC%E0%A7%8D%E0%A6%AF%E0%A6%BE%E0%A6%A8%E0%A7%8D%E0%A6%9F&amp;diff=6729&amp;oldid=prev"/>
		<updated>2026-10-15T09:07:07Z</updated>

		<summary type="html">&lt;p&gt;ইংরেজি উইকিপিডিয়ার “Taranabant” নিবন্ধের বাংলা অনুবাদ&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;vanc&lt;br /&gt;
[[File:Taranabant.svg|thumb]]&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot;&lt;br /&gt;
! colspan=&amp;quot;2&amp;quot; | তথ্যছক&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;watchedfields&amp;#039;&amp;#039;&amp;#039; || changed&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;verifiedrevid&amp;#039;&amp;#039;&amp;#039; || 448081332&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;iupac_name&amp;#039;&amp;#039;&amp;#039; || &amp;#039;&amp;#039;N&amp;#039;&amp;#039;-[(2&amp;#039;&amp;#039;S&amp;#039;&amp;#039;,3&amp;#039;&amp;#039;S&amp;#039;&amp;#039;)-4-(4-chlorophenyl)-3-(3-cyanophenyl)-2-butanyl]-2-methyl-2-&amp;lt;nowiki/&amp;gt;{[5-(trifluoromethyl)-2-pyridinyl]oxy}propanamide&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;width&amp;#039;&amp;#039;&amp;#039; || 250&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;pregnancy_au&amp;#039;&amp;#039;&amp;#039; || &amp;lt;!-- A / B1 / B2 / B3 / C / D / X --&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;pregnancy_us&amp;#039;&amp;#039;&amp;#039; || &amp;lt;!-- A / B            / C / D / X --&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;legal_au&amp;#039;&amp;#039;&amp;#039; || &amp;lt;!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled--&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;legal_ca&amp;#039;&amp;#039;&amp;#039; || &amp;lt;!-- Schedule I, II, III, IV, V, VI, VII, VIII --&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;legal_uk&amp;#039;&amp;#039;&amp;#039; || &amp;lt;!-- GSL, P, POM, CD, or Class A, B, C --&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;legal_us&amp;#039;&amp;#039;&amp;#039; || &amp;lt;!-- OTC / Rx-only / Schedule I, II, III, IV, V --&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;legal_status&amp;#039;&amp;#039;&amp;#039; || পরীক্ষাধীন (ব্যর্থ)&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;routes_of_administration&amp;#039;&amp;#039;&amp;#039; || মুখগহ্বর (Oral)&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Pharmacokinetic data--&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;excretion&amp;#039;&amp;#039;&amp;#039; || &amp;lt;!--Identifiers--&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;cas_number_ref&amp;#039;&amp;#039;&amp;#039; || ??&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;cas_number&amp;#039;&amp;#039;&amp;#039; || 701977-09-5&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;atc_prefix&amp;#039;&amp;#039;&amp;#039; || A08&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;atc_suffix&amp;#039;&amp;#039;&amp;#039; || AX&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;pubchem&amp;#039;&amp;#039;&amp;#039; || 11226090&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;drugbank_ref&amp;#039;&amp;#039;&amp;#039; || drugbank&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;unii_ref&amp;#039;&amp;#039;&amp;#039; || FDA&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;unii&amp;#039;&amp;#039;&amp;#039; || X9U622S114&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;chemspiderid&amp;#039;&amp;#039;&amp;#039; || 9401143&lt;br /&gt;
&lt;br /&gt;
&amp;lt;!--Chemical data--&amp;gt;&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;c&amp;#039;&amp;#039;&amp;#039; || 27&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;h&amp;#039;&amp;#039;&amp;#039; || 25&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;cl&amp;#039;&amp;#039;&amp;#039; || 1&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;f&amp;#039;&amp;#039;&amp;#039; || 3&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;n&amp;#039;&amp;#039;&amp;#039; || 3&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;o&amp;#039;&amp;#039;&amp;#039; || 2&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;smiles&amp;#039;&amp;#039;&amp;#039; || C[C@@H]([C@@H](CC1=CC=C(C=C1)Cl)C2=CC=CC(=C2)C#N)NC(=O)C(C)(C)OC3=NC=C(C=C3)C(F)(F)F&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;stdinchi&amp;#039;&amp;#039;&amp;#039; || 1S/C27H25ClF3N3O2/c1-17(34-25(35)26(2,3)36-24-12-9-21(16-33-24)27(29,30)31)23(14-18-7-10-22(28)11-8-18)20-6-4-5-19(13-20)15-32/h4-13,16-17,23H,14H2,1-3H3,(H,34,35)/t17-,23+/m0/s1&lt;br /&gt;
|-&lt;br /&gt;
| &amp;#039;&amp;#039;&amp;#039;stdinchikey&amp;#039;&amp;#039;&amp;#039; || QLYKJCMUNUWAGO-GAJHUEQPSA-N&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;টারানাব্যান্ট&amp;#039;&amp;#039;&amp;#039; (কোডনাম &amp;#039;&amp;#039;&amp;#039;MK-0364&amp;#039;&amp;#039;&amp;#039;) হলো একটি [[wikipedia:Cannabinoid receptor type 1|ক্যানাবিনয়েড রিসেপ্টর টাইপ ১ (CB&amp;lt;sub&amp;gt;1&amp;lt;/sub&amp;gt;)]] [[ইনভার্স অ্যাগোনিস্ট|ইনভার্স অ্যাগোনিস্ট]], যা এর [[wikipedia:Anorectic|অ্যানোরেক্টিক]] (ক্ষুধা দমনকারী) প্রভাবের কারণে [[wikipedia:Obesity|স্থূলতা]] চিকিৎসার সম্ভাব্য ওষুধ হিসেবে গবেষণাধীন ছিল।&amp;lt;ref&amp;gt;(2007). &amp;quot;Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists&amp;quot;. &amp;#039;&amp;#039;Bioorganic &amp;amp; Medicinal Chemistry Letters&amp;#039;&amp;#039;. 17 (8) 2184–7. doi:[https://doi.org/10.1016/j.bmcl.2007.01.087 10.1016/j.bmcl.2007.01.087].&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;(Jun 2007). &amp;quot;Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents&amp;quot;. &amp;#039;&amp;#039;Journal of Pharmacology and Experimental Therapeutics&amp;#039;&amp;#039;. 321 (3) 1013–22. doi:[https://doi.org/10.1124/jpet.106.118737 10.1124/jpet.106.118737].&amp;lt;/ref&amp;gt; এটি [[wikipedia:Merck &amp;amp; Co.|Merck &amp;amp; Co.]] কর্তৃক উদ্ভাবিত হয়েছিল।&lt;br /&gt;
&lt;br /&gt;
২০০৮ সালের অক্টোবরে, মার্ক এই ওষুধের [[wikipedia:Clinical trials#Phase III|তৃতীয় ধাপের (Phase III)]] [[wikipedia:Clinical trials|ক্লিনিক্যাল ট্রায়াল]] বন্ধ করে দেয়। এর কারণ ছিল ওষুধটির ব্যবহারের ফলে [[wikipedia:Central nervous system|কেন্দ্রীয় স্নায়ুতন্ত্রের]] ওপর উচ্চমাত্রার পার্শ্বপ্রতিক্রিয়া, যার মধ্যে প্রধান ছিল [[wikipedia:Depression (mood)|বিষণ্নতা]] এবং [[wikipedia:Anxiety|উদ্বেগ]]।&amp;lt;ref name=&amp;quot;urlMerck News Item&amp;quot;&amp;gt;[http://www.merck.com/newsroom/press_releases/research_and_development/2008_1002.html Press release by Merck].&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;pmid20157323&amp;quot;&amp;gt;(May 2010). &amp;quot;A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study&amp;quot;. &amp;#039;&amp;#039;International Journal of Obesity&amp;#039;&amp;#039;. 34 (5) 919–35. doi:[https://doi.org/10.1038/ijo.2010.21 10.1038/ijo.2010.21].&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;pmid20518807&amp;quot;&amp;gt;(June 2010). &amp;quot;A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes&amp;quot;. &amp;#039;&amp;#039;Diabetes, Obesity &amp;amp; Metabolism&amp;#039;&amp;#039;. 12 (6) 517–31. doi:[https://doi.org/10.1111/j.1463-1326.2009.01188.x 10.1111/j.1463-1326.2009.01188.x].&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;pmid20212496&amp;quot;&amp;gt;(August 2010). &amp;quot;A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study&amp;quot;. &amp;#039;&amp;#039;International Journal of Obesity&amp;#039;&amp;#039;. 34 (8) 1243–54. doi:[https://doi.org/10.1038/ijo.2010.38 10.1038/ijo.2010.38].&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== আরও দেখুন ==&lt;br /&gt;
* [[ক্যানাবিনয়েড রিসেপ্টর অ্যান্টাগনিস্ট|ক্যানাবিনয়েড রিসেপ্টর অ্যান্টাগোনিস্ট]]&lt;br /&gt;
&lt;br /&gt;
== তথ্যসূত্র ==&lt;br /&gt;
&amp;lt;references /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
----&lt;br /&gt;
&amp;#039;&amp;#039;উৎস:&amp;#039;&amp;#039; ইংরেজি উইকিপিডিয়ার “Taranabant” নিবন্ধের অনুবাদ।&lt;br /&gt;
&amp;#039;&amp;#039;মূল নিবন্ধ:&amp;#039;&amp;#039; https://en.wikipedia.org/wiki/Taranabant&lt;br /&gt;
&amp;#039;&amp;#039;এই অনুবাদটি স্বয়ংক্রিয়ভাবে প্রস্তুত করা হয়েছে।&amp;#039;&amp;#039;&lt;/div&gt;</summary>
		<author><name>Digantasen</name></author>
	</entry>
</feed>